About Argininosuccinate synthase
Argininosuccinate synthase (ASS1) is a protein
from Homo sapiens identified by UniProt accession
P00966, 412 residues long.
MolForge cross-references it against 0 known binders and
341 disease associations.
Target properties
| Protein name | Argininosuccinate synthase |
| UniProt accession | P00966 |
| Gene | ASS1 |
| Organism | Homo sapiens |
| Length | 412 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (341)
Diseases linked to this target (Open Targets).
- citrullinemia type I · score 0.85
- citrullinemia · score 0.71
- genetic disorder · score 0.47
- Intellectual disability · score 0.37
- acute neonatal citrullinemia type I · score 0.37
- adult-onset citrullinemia type I · score 0.37
- citrullinemia type II · score 0.34
- bone density · score 0.34
- urate measurement · score 0.34
- lung carcinoma · score 0.33
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P00966-F1 | alphafold | PREDICTED | 95.52 | — |
Amino-acid sequence (412 residues)
MSSKGSVVLA YSGGLDTSCI LVWLKEQGYD VIAYLANIGQ KEDFEEARKK ALKLGAKKVF IEDVSREFVE EFIWPAIQSS ALYEDRYLLG TSLARPCIAR KQVEIAQREG AKYVSHGATG KGNDQVRFEL SCYSLAPQIK VIAPWRMPEF YNRFKGRNDL MEYAKQHGIP IPVTPKNPWS MDENLMHISY EAGILENPKN QAPPGLYTKT QDPAKAPNTP DILEIEFKKG VPVKVTNVKD GTTHQTSLEL FMYLNEVAGK HGVGRIDIVE NRFIGMKSRG IYETPAGTIL YHAHLDIEAF TMDREVRKIK QGLGLKFAEL VYTGFWHSPE CEFVRHCIAK SQERVEGKVQ VSVLKGQVYI LGRESPLSLY NEELVSMNVQ GDYEPTDATG FININSLRLK EYHRLQSKVT AK
Explore Argininosuccinate synthase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets